|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Janssen to use Ichor's DNA drug delivery technology in hep B vaccines
Apr 13 2015, 09:28 ET | By: Douglas W. House, SA News Editor [Contact this editor with comments or a news tip]
Privately-held Ichor Medical Systems and Janssen Pharmaceuticals (NYSE:JNJ) enter into a product development collaboration and worldwide license agreement to develop and commercialize DNA-based vaccine products for the treatment of chronic hepatitis B infection utilizing Ichor's drug administration-boosting TriGrid electroporation technology.
Electroporation is a molecular biology technique in which an electrical field is applied to cells in order to increase the permeability of the cell membranes thereby facilitating the introduction of drugs into the cells.
Ichor's TriGrid Delivery System increases DNA drug delivery up to 1,000x compared to conventional injection.
Under the terms of the agreement, Ichor will receive an upfront payment, R&D support and development and sales milestones of up to $85M in addition to royalties on commercial sales of licensed products. Janssen will assume responsibility for certain development costs and all commercial costs associated with the partnership, including manufacturing and distribution expenses for TriGrid.
|
|
发表于 2015-4-14 09:54
